For the quarter ended September 2025, United Therapeutics (UTHR) reported revenue of $799.5 million, up 6.8% over the same period last year. EPS came in at $7.16, compared to $6.39 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $817.8 million, representing a surprise of -2.24%. The company delivered an EPS surprise of +3.92%, with the consensus EPS estimate being $6.89.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how United Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- United States: $774.8 million versus $810.22 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8% change.
- Revenues- Rest-of-World: $24.7 million versus $33.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -21.8% change.
- Revenues- Tyvaso- U.S.: $470.1 million versus the two-analyst average estimate of $507.8 million.
- Revenues- Unituxin- U.S.: $46.5 million versus $62.24 million estimated by two analysts on average.
- Revenues- Adcirca: $9.7 million versus $5.49 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +38.6% change.
- Revenues- Orenitram: $131.1 million versus $124.02 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +15.8% change.
- Revenues- Tyvaso: $478 million versus $484.44 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +10.2% change.
- Revenues- Remodulin: $125.9 million versus the five-analyst average estimate of $130.18 million. The reported number represents a year-over-year change of -1.9%.
- Revenues- Unituxin: $47.9 million versus $60.94 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -21.6% change.
- Revenues- Tyvaso DPI: $336.2 million versus the four-analyst average estimate of $322.54 million. The reported number represents a year-over-year change of +22.4%.
- Revenues- Nebulized Tyvaso: $141.8 million versus $157.39 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -10.9% change.
- Revenues- Other products: $6.9 million compared to the $5.35 million average estimate based on four analysts. The reported number represents a change of +25.5% year over year.
View all Key Company Metrics for United Therapeutics here>>>
Shares of United Therapeutics have returned -0.9% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
United Therapeutics Corporation (UTHR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
